Vascular endothelial growth factor: basic science and clinical progress.

By N. Ferrara. Endocrine reviews, 2004

3,786 citations recorded by the source corpus.

Subfields: Cancer Research, Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/794177181f84aeef6a765de33210a02a190e8744

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. N. Ferrara
2. A. Adamis
3. H. Gerber
4. R. Roskoski
5. W. Novotny
6. Kenneth J. Hillan
7. R. Langley
8. Paul Martin

In Cell Biology

1. Paul Martin
2. M. Tomic‐Canic
3. S. Eming
4. R. Roskoski
5. H. Gerber
6. A. Adamis
7. I. J. Fidler
8. R. Langley

In Molecular Biology

1. N. Ferrara
2. A. Adamis
3. H. Gerber
4. R. Roskoski
5. W. Novotny
6. Kenneth J. Hillan
7. Paul Martin
8. S. Eming

Citations in the corpus

• Vascular endothelial growth factor in eye disease. (2008, background): “Of these growth factors, VEGF is essential for proper physiological angiogenesis (Ferrara, 2004).”
• PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. (2009, background): “In vivo, VEGF-A concentrations were highest in TAF-EL4 implants.”
• Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. (2005, background): “Targeted gene disruption experiments in mice have revealed that loss of even a single allele of VEGF (hemizygosity) induces an embryonic lethal phenotype with gross vascular abnormalities demonstrating a dosedependent requirement for VEGF in vasculogenesis (Ferrara, 2004).”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “A Phase II trial recently reported that the anti-PDGFB aptamer pegpleranib (Fovista; OphthoTech) combined with ranibizumab significantly improved visual acuity over ranibizumab alone 236,237 , leading to the progression of this agent to Phase III trials.”
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, background): “There is now much evidence to indicate that VEGF 165 is the most physiologically relevant isofor”
• Biology of vascular endothelial growth factors (2006, background): “cytokines and hormones also up-regulate VEGF-A mRNA expression [17].”
• The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs (2011, background): “The proangiogenic cytokine VEGF is overexpressed in the majority of human tumors and is a central regulator of pathologic angiogenesis.(88) Several therapeutic agents designed to inhibit VEGF-induced angiogenesis are now in clinical use”
• Tumour vascular targeting (2005, background): “The contribution of VEGFA to cancer progression has been highlighted by the recent approval of the humanized anti-VEGF monoclonal antibody bevacizumab (Avastin; Genentech) for first-line cancer treatmen”
• Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. (2005, background): “One of the most potent positive regulators of angiogenesis is VEGF (11).”